Phase 2Not yet recruitingGeroscience intervention
Effect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects and Impacts of Supplemental Pentadecanoic Acid on Red Blood Cell Health and Activity and Predicted Biological Age in Healthy Older Adults
- Sponsor
- ReCellience15, Inc (Industry)
- Enrolment
- 93 planned
- Conditions
- Red Blood Cell Health; Biological Aging; Healthy Aging
- Interventions
- Pentadecanoic Acid; Placebo
- Ages
- adults, older adults
- Registry
- NCT07812792
Full record on ClinicalTrials.gov
From the registry
This Phase II randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effects of pentadecanoic acid (C15:0) supplementation on red blood cell (RBC) health and predicted biological age in healthy adults aged 55 years and older. A total of 93 participants will be randomized to receive 200 mg of C15:0, 300 mg of C15:0, or placebo daily for approximately 12 weeks. The primary objective is to assess the effect of C15:0 on red blood cell distribution width (RDW-CV), a marker of RBC health, compared with placebo. Secondary outcomes include measures of inflammation, hematologic and iron metabolism markers, circulating C15:0 levels, biological age-related biomarkers, sleep quality, fatigue, energy, and health-related quality of life. Safety and tolerability will also be evaluated throughout the study.
Primary outcomes
- To assess the effect of the test product (TP) at two dose levels on red blood cell (RBC) health, as measured by red blood cell distribution width (RDW), compared to placebo
History
Primary completion expected
Expected to start
Last registry update
Registered